PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on March 4, 2026. It represents a primary source document for Japanese Ticker:4889 sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: March 04, 2026, 15:30 JST Published by Pulse News Wire: March 04, 2026, 15:46 JST Renascience Inc. [4889.T] TOKYO, Mar 04 (Pulse News Wire) – Renascience Inc. (4889.T) completed its multicenter clinical trial for a disposable ultra-thin endoscope used in peritoneal dialysis patients. The study involved 60 cases, with initial and follow-up examinations conducted after 12 months. All procedures were deemed safe without adverse events reported. The device allows no